RSSS:NASDAQResearch Solutions, Inc Analysis
Data as of 2026-05-20 - not real-time
$2.12
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Research Solutions, Inc. (RSSS) is trading at $2.12, well below its 20‑day ($2.50) and 50‑day ($2.42) simple moving averages, indicating short‑term weakness, while the RSI of 36 suggests the stock is approaching oversold territory. The MACD histogram remains negative and the signal line is bullish‑biased, reinforcing a bearish technical bias, yet volume is on an upward trend, hinting at potential accumulation. On the valuation side, the price‑to‑earnings ratio of 14.1 is dramatically lower than the industry average of 38, and the discounted cash‑flow fair value of $2.47 sits above the current price, pointing to an undervalued position with approximately 15% upside.
Fundamentally, the company posted a 9.3% profit margin, a strong 29.8% ROE, and generated $5.45 M of free cash flow, all while maintaining a debt‑free balance sheet and $12 M of cash. Recent earnings news highlighted an 8.5% increase in ARR to $22.1 M and a 14% YoY rise in adjusted EBITDA, demonstrating growth in recurring revenue despite a 4.3% decline in total revenue. Analyst consensus is a “strong buy” with a median price target of $4.00, suggesting an upside of roughly 80%.
Fundamentally, the company posted a 9.3% profit margin, a strong 29.8% ROE, and generated $5.45 M of free cash flow, all while maintaining a debt‑free balance sheet and $12 M of cash. Recent earnings news highlighted an 8.5% increase in ARR to $22.1 M and a 14% YoY rise in adjusted EBITDA, demonstrating growth in recurring revenue despite a 4.3% decline in total revenue. Analyst consensus is a “strong buy” with a median price target of $4.00, suggesting an upside of roughly 80%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below key moving averages and bearish MACD
- RSI indicating near‑oversold condition
- Increasing volume suggesting potential buying interest
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation metrics (low PE vs industry, DCF fair value above market)
- Strong profitability (9.3% net margin, 29.8% ROE) and cash generation
- Positive earnings narrative with ARR and EBITDA growth
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Debt‑free balance sheet with ample cash reserves
- Strategic position in AI‑powered research SaaS market
- Long‑term upside potential reflected in analyst price targets and high upside/downside percentage
Key Metrics & Analysis
Financial Health
Revenue Growth-4.30%
Profit Margin9.28%
P/E Ratio14.1
ROE29.82%
ROA5.42%
P/B Ratio3.9
Op. Cash Flow$5.8M
Free Cash Flow$5.4M
Industry P/E38.0
Technical Analysis
TrendNeutral
RSI36.2
Support$2.00
Resistance$2.75
MA 20$2.50
MA 50$2.42
MA 200$2.86
MACDBearish
VolumeIncreasing
Fear & Greed Index89.18
Valuation
Fair Value$2.47
Target Price$3.83
Upside/Downside80.82%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.78
Volatility69.76%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.